14 assets in Histiocytic Sarcoma

Therapeutic assets addressing Histiocytic Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ensartinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
PI3K/MTOR INHIBITOR LY3023414 Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Tazemetostat Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Vemurafenib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (52)
q702 Histiocytic Sarcoma	Mayo Clinic	P1	CC (43)